Phase III study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.

被引：10

作者：

Armstrong, Andrew J.

Szmulewitz, Russell Zelig

Petrylak, Daniel Peter

Villers, Arnauld

Azad, Arun

Alcaraz, Antonio

Alekseev, Boris Y.

Iguchi, Taro

Shore, Neal D.

Rosbrook, Brad

Sugg, Jennifer

Baron, Benoit

Chen, Lucy F.

Stenzl, Arnulf

机构：

[1] Duke Canc Inst, Durham, NC USA

[2] Duke Prostate & Urol Canc Ctr, Durham, NC USA

[3] Univ Chicago, Chicago, IL 60637 USA

[4] Yale Canc Ctr, New Haven, CT USA

[5] Lille Univ, Univ Hosp Ctr, Dept Urol, Lille, France

[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[7] Hosp Clin Barcelona, Dept Urol, Barcelona, Spain

[8] Minist Hlth Russian Federat, PA Herzen Moscow Oncol Res Inst, Moscow, Russia

[9] Osaka City Univ, Grad Sch Med, Osaka, Japan

[10] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[11] Pfizer Inc, La Jolla, CA USA

[12] Astellas Pharma Inc, Northbrook, IL USA

[13] B Value, Leiden, Netherlands

[14] Eberhard Karls Univ Tubingen, Dept Urol, Tubingen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期

关键词：

D O I：

10.1200/JCO.2019.37.7_suppl.687

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

687

引用

页数：2

共 50 条

[1] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial
Horvath, Lisa
Armstrong, Andrew J.
Szmulewitz, Russell
Petrylak, Daniel
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33
[2] ARCHES: Efficacy of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC).
Armstrong, Andrew J.
Szmulewitz, Russell Zelig
Petrylak, Daniel Peter
Holzbeierlein, Jeffrey M.
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Yakovlevich
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Chen, Lucy F.
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[3] Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC)
Iguchi, Taro
Pu, Yeong-Shiau
Kimura, Go
Byun, Seok-Soo
Ha, Hong Koo
Hong, Jun Hyuk
Li, Jian-Ri
Sugg, Jennifer
Haas, Gabriel P.
Stenzl, Arnulf
Armstrong, Andrew J.
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 96 - 97
[4] China ARCHES: A multicenter phase III randomized doubleblind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) vs PBO plus ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Zhou, F.
Gongqian, Z.
Guo, H.
Hu, Z.
Zhang, X.
He, D.
He, Z.
Zhang, D.
Li, Y.
Kadeerbai, H.
Liu, Y.
Ye, D.
ANNALS OF ONCOLOGY, 2023, 34 : S971 - S971
[5] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Stenzl, A.
Szmulewitz, R. Z.
Petrylak, D. P.
Holzbeierlein, J.
Villers, A.
Azad, A. A.
Alcaraz, A.
Alekseev, B. Y.
Iguchi, T.
Shore, N. D.
Rosbrook, B.
Baron, B.
Haas, G. P.
Morlock, R.
Ramaswamy, K.
Armstrong, A. J.
ANNALS OF ONCOLOGY, 2019, 30 : 332 - +
[6] Phase 3 Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Metastatic Hormone-Sensitive Prostate Cancer: the ARCHES Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 10 - 12
[7] Arches - the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): post hoc analyses of high and low disease volume and risk groups
Hong, Jun Hyuk
Stenzl, Arnulf
Szmulewitz, Russell Z.
Petrylak, Daniel
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris Y.
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Baron, Benoit
Haas, Gabriel P.
Morlock, Robert
Ramaswamy, Krishnan
Armstrong, Andrew J.
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 102 - 103
[8] Androgen deprivation therapy with enzalutamide or placebo in metastatic hormone-sensitive prostate cancer: ARCHES
von Bueren, Moritz
Armstrong, Andrew J.
Szmulewitz, Russell
Petrylak, Daniel
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
SWISS MEDICAL WEEKLY, 2019, 149 : 16S - 16S
[9] ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Alcaraz, A.
Szmulewitz, R. Z.
Shore, N.
Crawford, E. D.
Petrylak, D. P.
Holzbeierlein, J.
Villers, A.
Azad, A. A.
Alekseev, B.
Iguchi, T.
Gomez-Veiga, F.
Rosbrook, B.
Sugg, J.
Haas, G. P.
Stenzl, A.
Armstrong, A. J.
ANNALS OF ONCOLOGY, 2020, 31 : S523 - S524
[10] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Armstrong, Andrew J.
Szmulewitz, Russell Z.
Petrylak, Daniel P.
Holzbeierlein, Jeffrey
Villers, Arnauld
Azad, Arun
Alcaraz, Antonio
Alekseev, Boris
Iguchi, Taro
Shore, Neal D.
Rosbrook, Brad
Sugg, Jennifer
Baron, Benoit
Chen, Lucy
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) : 2974 - +

← 1 2 3 4 5 →